As shown in Tables 3, 4 (pre rows), the results suggest that apixaban and rivaroxaban did not affect the thrombophilia tests (protein C, protein S and ATIII) as the mean values of these parameters with the addition of the DOAC are related to the controls without the DOAC and remained within the abnormal range. This evidence concerns the gene PROS1 and Rare hereditary thrombophilia.